Chronic Inhibition of Hypoxia-inducible Factor Prolyl 4-hydroxylase Improves Ventricular Performance, Remodeling, and Vascularity After Myocardial Infarction in the Rat
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Hypoxia inducible factors (HIFs) are transcription factors that are regulated by HIF-prolyl 4-hydroxylases (PHDs) in response to changes in oxygen tension. Once activated, HIFs play an important role in angiogenesis, erythropoiesis, proliferation, cell survival, inflammation, and energy metabolism. We hypothesized that GSK360A, a novel orally active HIF-PHD inhibitor, could facilitate local and systemic HIF-1 alpha signaling and protect the failing heart after myocardial infarction (MI). METHODS AND RESULTS: GSK360A is a potent (nanomolar) inhibitor of HIF-PHDs (PHD1>PHD2 = PHD3) capable of activating the HIF-1 alpha pathway in a variety of cell types including neonatal rat ventricular myocytes and H9C2 cells. Male rats treated orally with GSK360A (30 mg x kg x d) had a sustained elevation in circulating levels of erythropoietin and hemoglobin and increased hemoxygenase-1 expression in the heart and skeletal muscle. In a rat model of established heart failure with systolic dysfunction induced by ligation of left anterior descending coronary artery, chronic treatment with GSK360A for 28 days prevented the progressive reduction in ejection fraction, ventricular dilation, and increased lung weight, which were observed in the vehicle-treated animals, for up to 3 months. In addition, the microvascular density in the periinfarct region was increased (>2-fold) in GSK360A-treated animals. Treatment was well tolerated (survival was 89% in the GSK360A group vs. 82% in the placebo group). CONCLUSIONS: Chronic post-myocardial infarction treatment with a selective HIF PHD inhibitor (GSK360A) exerts systemic and local effects by stabilizing HIF-1 alpha signaling and improves long-term ventricular function, remodeling, and vascularity in a model of established ventricular dysfunction. These results suggest that HIF-PHD inhibitors may be suitable for the treatment of post-MI remodeling and heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxygen sensing by HIF hydroxylases
Schofield, C. J., & Ratcliffe, P. J. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1366 · Cited by 2,068 · cited 1×
“The transcriptional activity of HIF is regulated by enzymatic actions of HIF prolyl 4-hydroxylases (PHDs) that hydroxylate the a subunit and target it for proteasomal degradation during normoxia.(4,5) PHDs include at least 3 isoforms, PHD1, PHD2, and PHD3, which are expressed in most tissues including the heart.”
MethodOxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1
Semenza, G. L. (2007) · Biochemical Journal · doi:10.1042/bj20070389 · Cited by 541 · cited 1×
“At the local level, PHD inhibition conveys tolerance to ischemia primarily through HIF-1a transcriptional regulation of survival and apoptosis pathways, glucose metabolism, oxidant stress, and angiogenesis.(4,24) Our survey of PHD inhibitor–induced gene regulation indicated that upregulation of HO-1 in the heart was a…”
BackgroundInhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease
Fraisl, P., Aragonés, J., & Carmeliet, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2761 · Cited by 326
Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure
Minamishima, Y. A., Moslehi, J., Bardeesy, N., Cullen, D., Bronson, R. T., & Kaelin, W. G. (2008) · Blood · doi:10.1182/blood-2007-10-117812 · Cited by 294
Nwogu, J. I., Geenen, D., Bean, M., Brenner, M. C., Huang, X., & Buttrick, P. M. (2001) · Circulation · doi:10.1161/hc4301.097193 · Cited by 131 · cited 3×
“Several studies have also demonstrated that chronic treatment with PHD inhibitors improves cardiac function in the rat after myocardial infarction (MI).(10,11) However, the mechanism of cardioprotection for PHD inhibitors is controversial because some of the tool compounds Received for publication February 16, 2010; a…”
BackgroundResult
Cited by
Hypoxia. 2. Hypoxia regulates cellular metabolism
Wheaton, W. W., & Chandel, N. S. (2011) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00485.2010 · Cited by 426
Angiogenesis after acute myocardial infarction
Wu, X., Reboll, M. R., Korf-Klingebiel, M., & Wollert, K. C. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa287 · Cited by 379
Pharmacologic Targeting of Hypoxia-Inducible Factors
Semenza, G. L. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021637 · Cited by 288
Targeting hypoxia-inducible factors: therapeutic opportunities and challenges
Yuan, X., Ruan, W., Bobrow, B., Carmeliet, P., & Eltzschig, H. K. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00848-6 · Cited by 245
A feedback regulatory loop between HIF‐1α and miR‐21 in response to hypoxia in cardiomyocytes
Liu, Y., Nie, H., Zhang, K., Ma, D., Yang, G., Zheng, Z., Liu, K., Yu, B., Zhai, C., & Yang, S. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.05.067 · Cited by 94
Metadata
- Authors
- Bao, W., Qin, P., Needle, S., Erickson-Miller, C. L., Duffy, K. J., Ariazi, J. L., Zhao, S., Olzinski, A. R., Behm, D. J., Teg Pipes, G. C., Jucker, B. M., Hu, E., Lepore, J. J., & Willette, R. N.
- Venue
- Journal of Cardiovascular Pharmacology
- Published
- 2010-08
- Volume
- 56
- Issue
- 2
- Pages
- 147-155
- ISSN
- 0160-2446 (ISSN-L)
- OpenAlex
- W2031385405
- Cited by
- 100
- References
- 5
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.